Application value of risk ovarian malignancy algorithm in early diagnosis of epithelial ovarian cancer
10.13481/j.1671-587x.20190428
- Author:
Yipin WANG
1
Author Information
1. Department of Obstetrics and Gynecology, Jilin University, China-Japan Union Hospital
- Publication Type:Journal Article
- Keywords:
Carbohydrate antigen 125;
Clinical diagnosis;
Human epididymis protein 4;
Ovarian neoplasms;
Risk ovarian malignancy algorithm
- From:
Journal of Jilin University(Medicine Edition)
2019;45(4):905-910
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the value of risk ovarian malignancy algorithm (ROMA) in evaluation of the risk of epithelial ovarian cancer and its association with the clinical pathological stages, and to provide a basis for the clinical diagnosis and treatment and prognosis analysis of epithelial ovarian cancer.Methods: The clinical materials of 135 patients with ovarian tumor confirmed by paraffin section pathology after operation were retrospectively analyzed. The patients were divided into benign ovarian tumor group(n=66), epithelial ovarian cancer group(n=58) and non-epithelial ovarian cancer group(n=11).According to the cutoff values of HE4,CA125,and ROMA of the patients in various groups,the positive rates of HE4,CA125,and ROMA of the patients in various groups were calculated.Based on the serum levels of human epididymis protein 4(HE4) and carbohydrate antigen 125(CA125) detected before operation of the patients in various groups, the relationships between the positive rates of serum HE4, CA125 and ROMA and the clinical stages of the patients with ovarian cancer;their diagnosis efficacies in the patients with ovarian cancer were evaluated. Results: The serum CA125, HE4 levels and ROMA value of the patients in epithelial ovarian cancer group were significantly higher than those in benign ovarian tumor group and non-epithelial ovarian cancer group (P<0.05). The positive rates of HE4, CA125, and ROMA of the patients in epithelial ovarian cancer group were higher than those in benign ovarian tumor group (P<0.01), and showed an increasing trend with the increase of clinical stages. Compared with the positive rates of HE4 and CA125, the ROMA had the lowest positive rate in the patients with ovarian benign tumor, and the positive rates of ROMA in all stages of epithelial ovarian cancer were higher than those of CA125.The sensitivity and the negative predictive value of ROMA in postmenopausal patients with ovarian cancer group were higher than those in premenopausal patients with ovarian cancer group (P<0.05), while the specificity and the positive predictive value were not significantly different between premenopausal and postmenopausal patients with ovarian cancer groups (P>0.05). Among the three indexes, ROMA had the highest diagnostic efficacy index and CA125 had the lowest.Conclusion: The diagnostic value of ROMA for evaluating the risk of epithelial ovarian cancer was higher than those of CA125 and HE4, which has a better diagnostic value for the postmenopausal patients and can improve the early diagnosis efficiency of ovarian cancer.
